Sarcoidosis is a multisystem disease that can involve almost any organ system. The underlying cause of the disease remains unknown. Immunopathologically and histologically, cutaneous sarcoidosis is characterized by a macrophage/T helper-1 cell-mediated, non-caseating, granulomatous inflammation process. An imbalance between proinflammatory and anti-inflammatory cytokines plays an important role in the development of cutaneous granulomas. Recognition of cutaneous sarcoidosis lesions is very important because they provide a visible clue to the diagnosis and are an easily accessible source of tissue for histologic examination. Because skin lesions of patients with the disease can exhibit many different morphologies, cutaneous sarcoidosis is known as one of the ‘great imitators’ in dermatology. Specific manifestations can include patches (sometimes hypopigmented), papules, scar sarcoidosis, ulcers, ichthyosis, and alopecia. The treatment of cutaneous sarcoidosis is often frustrating because some of the skin lesions may be refractory to treatment or may recur following successful treatment. Systemic and topical corticosteroids are the most effective treatments for cutaneous sarcoidosis.
This article focuses on the dermatologic aspects of sarcoidosis and includes a review of the most recent literature, which includes new data on the diagnosis, differential diagnosis, pathogenesis, and treatment of the disease.
No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.
Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982: epidemiology and clinical picture. Sarcoidosis 1990; 7 (1): 50-7PubMedGoogle Scholar
Rybicki BA, Major M, Popovich Jr J, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145 (3): 234-41PubMedCrossRefGoogle Scholar
McNicol MW, Luce PJ. Sarcoidosis in a racially mixed community. J R Coll Physicians Lond 1985; 19 (3): 179-83PubMedGoogle Scholar
Pesut D. The role of central registry in control and research of sarcoidosis in Serbia and Montenegro. Med Pregl 2005; 58: 7-10PubMedGoogle Scholar
Gras M, van Kemenade FJ, van Maarsseveen AC, et al. Sarcoidosis: immunopathogenesis and the potential of immunotherapy. Ned Tijdschr Geneeskd 2003; 147 (4): 150-5PubMedGoogle Scholar
Scharkoff T. Apropos of the present level of epidemiologic knowledge on sarcoidosis. Sarcoidosis 1987; 4 (2): 152-4PubMedGoogle Scholar
Shelly A, Gedalia A. Sarcoidosis [online]. Available from URL: http://www.emedicine.com/ped/topic2043.htm [Accessed 2006 Nov 16]Google Scholar
Mankiewicz E. Die Bedeutung lysogener Mykobakterien fdr die Atiologie der Sarkoidose. Arch Klin Exp Dermatol 1966: 227 (1): 63-77PubMedGoogle Scholar
Gazouli M, Ikonomopoulos J, Trigidou R, et al. Assesment of mycobacterial, propionibacterial and human herpesvirus DNA in tissues of Greek patients with sarcoidosis. J Clin Microbiol 2002; 40: 3060-3PubMedCrossRefGoogle Scholar
Fite E, Femandez-Figueras MT, Prats R, et al. High prevalence of Mycobacterium tuberculosis DNA in biopsies from sarcoidosis patients from Catalonia, Spain. Respiration 2006; 73 (1): 20-6PubMedCrossRefGoogle Scholar
di Gennaro G, Ganzonied V, Schioppa O, et al. Discordant HHV8 detection in a young HIV-negative patient with Kaposi’s sarcoma and sarcoidosis. Clin Infect Dis 2001; 32 (7): 1100-2PubMedCrossRefGoogle Scholar